Lv1
58 积分 2025-03-14 加入
Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases
3个月前
已完结
Inhibition of ROCK2 alleviates renal fibrosis and the metabolic disorders in the proximal tubular epithelial cells
4个月前
已完结
Advances and challenges in kidney fibrosis therapeutics
6个月前
已完结
Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease
6个月前
已完结
A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease
7个月前
已完结
Establishment of an orthotopic glioblastoma mouse model for preclinical studies
7个月前
已完结
Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands
7个月前
已完结
Discovery and characterization of SIM0711, a potent and selective IRAK4 PROTAC with enhanced efficacy and safety 4626
7个月前
已完结
Design, Synthesis, and Evaluation of Nucleolin-Bridged, MDM2-Recruiting IRAK4 Degraders for the Treatment of Autoimmune Diseases
7个月前
已完结
皖公网安备34019202002308
